|
Cyclerion Therapeutics Inc (NASDAQ: CYCN) |
|
Cyclerion Therapeutics Inc
CYCN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Cyclerion Therapeutics Inc growth rates, revenue grew
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Cyclerion Therapeutics Inc faced net loss in contrast to the net income a year ago in III. Quarter 2024
• More on CYCN's Growth
|
|
Cyclerion Therapeutics Inc realized a net loss in trailing twelve months.
Cyclerion Therapeutics Inc realized cash reduction of $ -2.47 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 38.93.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.86.
• More on CYCN's Valuation
|
|
|
|
|
Cyclerion Therapeutics Inc realized net loss in trailing twelve months.
Cyclerion Therapeutics Inc realized cash outflow of $ -2.47per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 38.93.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.86.
Cyclerion Therapeutics Inc Price to Book Ratio is at 0.92 lower than Industry Avg. of 1352.97. and higher than S&P 500 Avg. of 0.01
• More on CYCN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com